SCHEMBL14185293

SCHEMBL14185293

O=C(CCl)c1cccc(N(S(=O)(=O)c2ccccc2)S(=O)(=O)c2ccccc2)c1

nearest known ligand 0.50

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 4/20 0.50
TRPA1 O75762 1/20 0.50
MAPK1 P28482 1/20 0.50
GSK3B P49841 1/20 0.50
HIF1A Q16665 1/20 0.50
LMNA P02545 3/20 0.45
SMN1; SMN2 Q16637 2/20 0.42
HTT P42858 2/20 0.42
HSD11B1 P28845 4/20 0.42
TP53 P04637 1/20 0.41
KMT2A Q03164 2/20 0.41
GLA P06280 1/20 0.41
MEN1 O00255 1/20 0.41
PTPN1 P18031 1/20 0.40
F2 P00734 1/20 0.39
NPC1 O15118 1/20 0.39
POLB P06746 1/20 0.39
RAB9A P51151 1/20 0.39
NPSR1 Q6W5P4 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4603391 0.87 ESR1 (0.49) ALDH1A1TRPA1MAPK1GSK3BHIF1A
SCHEMBL8973992 0.83 ALDH1A1 (0.57) ALDH1A1LMNASMN1; SMN2HTTHSD11B1
SCHEMBL14185292 0.81 ALDH1A1 (0.51) ALDH1A1MAPK1LMNASMN1; SMN2HTT
SCHEMBL6496987 0.73 KMT2A (0.53) ALDH1A1TRPA1MAPK1GSK3BHIF1A
SCHEMBL7250273 0.73 KMT2A (0.53) ALDH1A1TRPA1MAPK1GSK3BHIF1A
SCHEMBL7914241 0.72 CA1 (0.58) ALDH1A1TRPA1MAPK1GSK3BHIF1A
SCHEMBL11576079 0.72 APOBEC3G (0.56) ALDH1A1LMNASMN1; SMN2KMT2A
SCHEMBL4606413 0.71 HDAC2 (0.60) KMT2AMEN1POLB
SCHEMBL11874771 0.71 ALDH1A1 (0.51) ALDH1A1TRPA1MAPK1GSK3BHIF1A
SCHEMBL8575784 0.71 HDAC3 (0.48) ALDH1A1MAPK1LMNASMN1; SMN2HSD11B1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20080103138-A1 Beta-agonists, methods for the preparation thereof and their use as pharmaceutical compositions BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2008-05-01 US disclosed
US-20080103138-A1 Beta-agonists, methods for the preparation thereof and their use as pharmaceutical compositions BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2008-05-01 US disclosed
US-20070112033-A1 N-(3-{2-[3-(6-amino-benzimidazol-1-yl)-1,1-dimethyl-propylamino]-1-hydroxy-ethyl}-phenyl)-benzenesulphonamide; beta(3)-Adrenoceptor agonists; antidiabetic, obesity, insulin resistance BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2007-05-17 US disclosed
US-20070112033-A1 N-(3-{2-[3-(6-amino-benzimidazol-1-yl)-1,1-dimethyl-propylamino]-1-hydroxy-ethyl}-phenyl)-benzenesulphonamide; beta(3)-Adrenoceptor agonists; antidiabetic, obesity, insulin resistance BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2007-05-17 US disclosed
WO-2007048842-A1 BENZIMIDAZOLE DERIVATIVES FOR USE AS BETA-3 RECEPTOR AGONISTS BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2007-05-03 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080103138-A1 Beta-agonists, methods for the preparation thereof and their use as pharmaceutical compositions ADRB1, ADRB3, ADRB2 ALDH1A1 717/4885TRPA1 543/4885MAPK1 2859/4885
US-20070112033-A1 N-(3-{2-[3-(6-amino-benzimidazol-1-yl)-1,1-dimethyl-propylamino]-1-hydroxy-ethyl}-phenyl)-benzenesulphonamide; beta(3)-Adrenoceptor agonists; antidiabetic, obesity, insulin resistance ADRB3, ADRB1, ADRA1B ALDH1A1 573/4885TRPA1 320/4885MAPK1 2434/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.